Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 08 - 24 tags : Disease save search
Cassava Sciences Announces Agreement with FDA on Special Protocol Assessments (SPA) for its Phase 3 Studies of Simufilam for the Treatment of Alzheimer’s Disease
Published: 2021-08-24 (Crawled : 13:00) - globenewswire.com
SAVA | $19.61 -7.46% -8.06% 1.3M
|
Health Technology
|
| O: 5.88%
H: 0.78%
C: -3.74%
disease alzheimer treatment fda phase 3 alzheimer’s alzheimer's disease alzheimer's
AllStripes Announces $50 Million Series B Financing to Advance Global Rare Disease Research
Published: 2021-08-24 (Crawled : 13:00) - biospace.com/
TSHA | $2.265 -6.02% -6.4% 1.8M
|
Health Technology
|
| O: 0.28%
H: 0.61%
C: -1.27%
disease research rare
Cassava Sciences Announces Agreement with FDA on Special Protocol Assessments (SPA) for its Phase 3 Studies of Simufilam for the Treatment of Alzheimer’s DiseasePhase 3 Study Initiation Still Expected Fall 2021
Published: 2021-08-24 (Crawled : 13:00) - biospace.com/
SAVA | $19.61 -7.46% -8.06% 1.3M
|
Health Technology
|
| O: 5.88%
H: 0.78%
C: -3.74%
disease alzheimer treatment fda phase 3 alzheimer’s alzheimer's
CytRx Highlights Orphazyme’s Published Results From Its Phase 2/3 Trial of Arimoclomol in Niemann-Pick Disease Type C
Published: 2021-08-24 (Crawled : 13:00) - biospace.com/
IBRX | $5.265 7.23% 6.74% 4.6M
|
Manufacturing
|
| O: 0.28%
H: 4.22%
C: 3.49%
disease phase 2 phase 2/3 results trial
Insights on the Autoimmune Disease Diagnostics Global Market to 2026 - by Gender, Technology, Indication and Region
Published: 2021-08-24 (Crawled : 12:15) - prnewswire.com
TMO | News | $544.78 0.6% 0.0% 1.7M
|
Health Technology
|
| O: 0.31%
H: 0.0%
C: -0.69%
disease technology diagnostics diagnostic
FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
Published: 2021-08-24 (Crawled : 12:00) - prnewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.35%
H: 0.12%
C: -0.9%
disease fda fda approval
Worldwide Protein Drugs Industry to 2026 - Prevalence of Chronic Diseases is Driving Growth
Published: 2021-08-24 (Crawled : 12:00) - prnewswire.com
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.67%
H: 0.0%
C: -1.04%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.35%
H: 0.12%
C: -0.9%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.3%
H: 0.0%
C: -0.03%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.69%
H: 0.42%
C: 0.1%
BMRN | $88.68 -1.54% -1.57% 1.8M
|
Health Technology
|
| O: -0.08%
H: 2.49%
C: 2.43%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.05%
H: 0.07%
C: -0.51%
disease drug growth
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.